USPSTF updates recommendations on risk-reducing breast cancer medication
Healthcare providers should offer risk-reducing medications such as tamoxifen, raloxifene and aromatase inhibitors to women at an increased risk of breast cancer or low risk of experiencing adverse effects, according to the U.S. Preventive Services Task Force (USPSTF). The full recommendation statement was published by JAMA.
